The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses.

LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.

The Series A investment round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital and existing investors. The round also included participation from Recursion Pharmaceuticals’ Founder & CEO Chris Gibson as well as Inovia Capital General Partner Patrick Pichette who was formerly Google’s CFO. Zavain Dar, Partner at Lux Capital and Nan Li, Managing Director at Obvious Ventures, will join the company’s board of directors.

LabGenius Founder and CEO, Dr. James Field, says

We’ve seen this playbook before. Bringing to bear multiple technologies to remove human bias from the pursuit of human health. We’re thrilled to co-lead the Series A with Obvious Ventures and back a truly bold vision with the potential for massive impact.

Nan Li, Managing Director at Obvious Ventures, said:

Silicon Canals for more European technology news.

https://siliconcanals.com/news/sponsh-dutch-startup-extract-water-air-fight-water-shortage%e2%80%8c/